Platelet Function in Patients Admitted with a Diagnosis of Myocardial Infarction

Mikhailidis, D. P.; Barradas, M. A.; Mier, A.; Boag, F.; Jeremy, J. Y.; Havard, C. W. H.; Dandona, P.
January 1987
Angiology;Jan1987 Part 1, Vol. 38 Issue 1, p36
Academic Journal
Platelet function and thromboxane A release were measured in 71 patients admitted to a coronary care unit with a provisional diagnosis of acute myocardial infarction (AMI). All measurements were carried out within twenty-four hours of admission. Of these, 35 patients had the diagnosis of AMI confirmed. The remainder (n=36), who did not have AMI (NMI), were divided into two groups: (a) those (n =18) with an unequivocal history of previous vascular disease and (b) those without vascular disease (n =18). Platelet aggregation and thromboxane A2 (TXA22) release were significantly increased in the AMI group when compared with those in the NMI without vascular disease group or a healthy control group with similar age and sex distribution. Aggregation and TXA22 release in the NMI patients with vascular disease were greater than those in controls and did not differ significantly from those in the AMI group. Patients in the AMI or MMI with vascular disease groups who were taking β-blockers or calcium channel antagonists at the time of admission showed significantly less platelet aggregation than those who were not taking these drugs. Heparin, added in vitro at therapeutic concentrations, induced significantly more aggregation in patients in the AMI and NMI with vascular disease groups than in the NMI without vascular disease group. We conclude that: (1) platelets obtained from patients with AMI are hyperaggregable and release more TXA2; (2) platelets from patients with significant vascular disease are hyperaggregable, even in the absence of AMI, although they are not as hyperaggregable as those from AMI; (3) treatment with nifedipine and fl-blockers protects these patients from platelet hyperaggregability; (4) heparin induces significant aggregation of platelets from patients with AMI and NMI with vascular disease. These observations are of importance in considering the pathogenesis and treatment of AMI and ischemic heart disease.


Related Articles

  • Beta--Blockers after Myocardial Infarction: Influence of First--Year Clinical Course on Long--Term Effectiveness. Viscoli, Catherine M.; Horwitz, Ralph I.; Singer, Burton H. // Annals of Internal Medicine;1/15/93, Vol. 118 Issue 2, p99 

    Presents a study that examined the influence of first year clinical course on the long-term effectiveness of the beta-blocker propranolol after myocardial infarction. Assessment of the mortality rates; Analysis of changes in the treatment of patients; Evaluation of the effectiveness of...

  • Post-MI therapy: Low-dose beta blockers may be as good as, maybe better than, high-dose.  // Geriatrics;Jun98, Vol. 53 Issue 6, p98 

    Presents a summary of the article `Beta-blocker dosages and mortality after myocardial infarction: Data from a large health maintenance organization,' by H.V. Barron, S. Viskin, R.J. Lundstrom and others, published in the March 9, 1998 issue of the `Archives of Internal Medicine' periodical.

  • Should every survivor of a heat attack be given a beta-blocker? Hampton, J.R.; Breckenridge, A.; Rose, Geoffrey // British Medical Journal (Clinical Research Edition);7/3/1982, Vol. 285 Issue 6334, p33 

    Part I, II and III. Focuses on the use of a beta-blocker in survivor of heart attack in Great Britain. Difficulty to use beta-blockers in the initial stages of a heart attack; Reduction of mortality in patients treated with beta-blockers; Administration of beta-blockers in patients due to...

  • Confidence in results of beta-blocker postinfarction trials. Baber, N.S.; Lewis, J.A. // British Medical Journal (Clinical Research Edition);6/12/1982, Vol. 284 Issue 6331, p1749 

    Examines the results of beta-blockers in myocardial infarctions. Reduction of mortality; Temporal distribution of trial admission; Improvements of technique for calculating confidence limits.

  • Half of MI patients don't get beta blockers; those who don't get enough.  // Modern Medicine;Sep95, Vol. 63 Issue 9, p38 

    Presents an abstract of the report `Treatment with beta-adrenergic blocking agents after myocardial infarction: From randomized trials to clinical practice,' by S. Viskin et. al. published on the May 1995 issue of `Journal of American College of Cardiology'.

  • ARRESTING ANGINA. Beyzarov, Elena // Drug Topics;9/27/2004, Vol. 148 Issue 18, p25 

    This article states that the American Heart Association recommended a combination of aspirin, unfractionated heparin, and platelet glycoprotein IIb/IIIa receptor antagonists for unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI). Beta-blockers are still used early to...

  • Myocardial infarction with angiographically normal coronary arteries. Chandrasekaran, B.; Kurbaan, A. S. // Journal of the Royal Society of Medicine;Aug2002, Vol. 95 Issue 8, p398 

    The article focuses on the myocardial infarction with normal coronary arteries (MINCA). MINCA symptoms and electrocardiographic (ECG) findings were similar to myocardial infarction (MI) with angiographic colonary disease except in its infarct size that tend to be smaller. Information related to...

  • Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. Quint, J. K.; Herrett, E.; Bhaskaran, K.; Timmis, A.; Hemingway, H.; Wedzicha, J. A.; Smeeth, L. // BMJ: British Medical Journal;1/4/2014, Vol. 348 Issue 7939, p13 

    The article discusses a study to determine whetherß blockers are associated with decreased mortality in patients with chronic obstructive pulmonary disease (COPD) having a first myocardial infarction. Patients with COPD with a first myocardial infarction from January 1, 2003 to December 31,...

  • Takotsubo cardiomyopathy. Cuculi, F.; Lim, C. C. S.; Banning, A. P. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/22/2010, Vol. 340 Issue 7756, p1095 

    The article offers clinical information on takotsubo cardiomyopathy, a condition characterized by acute, reversible left ventricular dysfunction that does not correlate with epicardial coronary artery blood supply. Takotsubo cardiomyopathy commonly affects postmenopausal women and is usually...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics